Biomedical subjects
W H Mosley
Publications and source records attributed to W H Mosley.
Serological evidence for the identity of the vascular permeability factor and ileal loop toxin of Vibrio cholerae.
Explore the source record for details and available documents.
The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests.
Explore the source record for details and available documents.
The spectrum of cholera in rural East Pakistan. I. Correlation of bacteriologic and serologic results.
Explore the source record for details and available documents.
Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae.
Explore the source record for details and available documents.
Isolation of Vibrio cholerae from nightsoil during epidemics of classical and E1 Tor Cholera in East Pakistan.
A clear difference has been observed between the classical Inaba V. cholerae and the El Tor Ogawa V. cholerae in relation to the ability to isolate the organism from the environment.An early attempt to utilize nightsoil sampling as a tool to measure the extent of infection in the community during an epidemic of classical Inaba cholera in Dacca, East Pakistan, in the spring and fall of 1968 proved unsuccessful. During an epidemic caused by both the classical Inaba and the El Tor Ogawa vibrios in Chittagong between July 1968 and March 1969 the reasons for this failure became apparent. In Dacca, only 2 isolations of classical Inaba were made from 9906 individual latrine and pooled communal nightsoil samples, whereas in Chittagong, from 62 588 similar samples in which 2 classical Inaba isolations were also made, there were 52 El Tor Ogawa isolations. In areas where cases due to both biotypes were occurring simultaneously, El Tor Ogawa vibrios were isolated 10 times more frequently than the classical Inaba.It remains unclear whether the differences observed between El Tor Ogawa and classical Inaba are related to the biotype or to the serotype of the organism, or to both. An extrapolation of nightsoil sampling, therefore, to the incidence and prevalence of infection in a community must consider both the biotype and the serotype.
Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas.
Explore the source record for details and available documents.
Vibriocidal antibody in clinical cholera.
Explore the source record for details and available documents.
Endemic cholera in rural East Pakistan.
Explore the source record for details and available documents.
Epidemiologic analysis of endemic cholera in urban East Pakistan, 1964-1966.
Explore the source record for details and available documents.
A community study of inapparent cholera infections.
Explore the source record for details and available documents.
Active and passive immunization in the adult rabbit ileal loop model as an assay for production of antitoxin immunity by cholera vaccines.
Three field trial cholera vaccines did not induce antitoxic immunity. A choleragenic toxin induced high-serum neutralizing antibody, but protection to loop challenge with toxin was minimal.
Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. I. Study design and results of the first year of observation.
A controlled cholera vaccine field trial was carried out in rural East Pakistan during the 1966-67 cholera season. A commercial cholera vaccine of average potency was tested in 40 000 children aged 3 months to 14 years in 1- and 2-dose schedules. In the cholera season extending for 8 months following immunization, a single dose produced an over-all protection of 46%; 2 doses at an interval of 1 month provided 64% protection. The single dose was virtually ineffective in children under 5 years, but provided significant protection in older children. The enhanced effect of the 2-dose schedule was primarily due to the boosting of protection in children under the age of 5 years. The duration of significant protection, even with the 2-dose schedule, did not appear to extend beyond the first 3 months of the 8-month cholera season.
Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae.
The 1966-67 cholera vaccine field trials in East Pakistan tested 1- and 2-dose schedules of a commercial cholera vaccine in 40 000 children aged 3 months to 14 years. Randomsample serological surveys, made prior to the inoculations and 3 months and 6 months after the inoculations, demonstrated that there was a rise in the vibriocidal titres of the vaccinated children during the first 3 months after inoculation and a subsequent fall by the end of the second 3 months. The antibody response to 2 doses of cholera vaccine was better than the response to a single dose in children under 5 years of age. In children aged 5-14 years, the antibody response was similar for both inoculation schedules. Since the majority of the older children had vibriocidal antibodies before inoculation, the data suggest that the single dose acted as a booster, and this effect was not enhanced by a second inoculation.Serological studies of the hospitalized cholera patients indicated that the majority had low vibriocidal titres on admission to hospital. By comparing the distribution of admission titres of the hospitalized patients with the distribution of titres found in the population survey, it was possible to demonstrate a progressive reduction in the cholera case rate for the population with high levels of vibriocidal antibody.The sample surveys from the control population revealed a rise in titre following the peak of the cholera season, and a fall 3 months later. The data suggest that the rate of infection with V. cholerae for the 10 000 children in the control group during the cholera season may have been as high as 27%, while the clinical case rate was only 0.26%.
Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 3. The lack of effect of prior vaccination or circulating vibriocidal antibody on the severity of clinical cholera.
In a controlled study, it has been shown that the prior administration of cholera vaccine had no beneficial effect on the clinical course of cholera as measured by either the condition of the patient on admission to hospital or the subsequent course of the disease. In fact, the disease was, if anything, more severe in those who had received cholera vaccine. Although the presence of a high vibriocidal titre is associated with protection from cholera, pre-existing antibody had no effect on the clinical course of the disease in those patients who developed cholera.
Neutralization of the vascular permeability factor of Vibrio Cholerae in man.
Explore the source record for details and available documents.
Tetracycline prophylaxis in families of cholera patients.
The evaluation of tetracycline as a chemoprophylactic agent for cholera is described. Families of cholera patients were divided into 4 groups by strict rotation. The first group received multivitamin preparations and served as the control. The second received 1.0 g of tetracycline, divided into 4 doses, daily for 5 days, the third received 1.0 g of tetracycline in a single dose daily for 5 days, and the fourth received a single dose of 1.0 g of tetracycline. All families were visited daily for 10 days, a rectal swab being taken from each family member on each occasion. Tetracycline given daily for 5 days, either in divided doses or in a single daily dose, was effective in preventing subsequent infection. A single dose of tetracycline was less effective. The indications for chemoprophylaxis in cholera are discussed.